help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zumbach, M. S.
Right arrow Articles by Nawroth, P. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zumbach, M. S.
Right arrow Articles by Nawroth, P. P.
The Journal of Clinical Endocrinology & Metabolism Vol. 82, No. 12 4080-4082
Copyright © 1997 by The Endocrine Society

Original Studies

Tumor Necrosis Factor Increases Serum Leptin Levels in Humans

Martina Susanne Zumbach, Michael Wolfgang Josef Boehme, Peter Wahl, Wolfgang Stremmel, Reinhard Ziegler and Peter Paul Nawroth1

Department of Medicine, University of Heidelberg, 69115 Heidelberg, Germany

Address correspondence and requests for reprints to: Dr. P. Nawroth, Medizinische Klinik, Bergheimer Strasse 58, 69115 Heidelberg, Germany.


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Leptin is a pleiotropic hormone believed to regulate body weight. Its function in wasting during inflammatory disease in humans is unknown.

We studied the effect of repeated tumor necrosis factor (TNF) infusion on serum leptin levels in six patients with solid tumors.

TNF infusion on day 1 resulted in an increase in serum leptin levels from 3.1 (SEM ± 0.28) ng/mL to 5.2 (SEM ± 0.6) ng/mL after 12 h (P < 0.001). The serum levels returned to baseline within 24 h. Similar results were obtained when TNF was infused on subsequent days. The study shows that leptin serum levels are under control of TNF.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
WEIGHT LOSS in diseases with chronically activated host response has been the focus of previous studies, including the isolation of cachectin, later characterized as tumor necrosis factor (TNF) (1). Loss of appetite and weight is a hallmark of chronic inflammatory disease. Leptin is presumed to play a role in controlling not only food intake but also weight, by additional, as yet unknown, mechanisms (2, 3). Leptin has been studied primarily with respect to obesity (3), but not with respect to loss of appetite and wasting in cytokine-mediated chronic disease. Recently it has been shown in hamsters that cytokines affect leptin serum levels (4). This study was designed to evaluate whether leptin in humans is under the control of cytokines.


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
Table 1Go shows the successive serum samples of six patients, who received altogether a total of 16 courses of iv recombinant human TNF-{alpha} therapy (Knoll AG, Ludwigshafen, Germany) (120 µg/m2 body surface) (5). At each time point we obtained 16 serum samples. The leptin value presented is the mean of 16 leptin determinations. TNF was infused over 2 h daily, over 5 days. The infusions were always given in the late morning. All patients had breakfast before. If applicable, this course was repeated after 21 days. In addition, all patients received an sc therapy with interferon {alpha}-2 (5 x 106U sc on each consecutive day without interruption). The clinincal efficiency of the therapy was poor, as reported previously (5). All patients were treated according to protocols of phase II clinical trials, approved by The Ethics Committee of the University of Heidelberg. The body mass index and the baseline serum leptin levels were within the normal range (6).


View this table:
[in this window]
[in a new window]
  		Table 1. Clinical characteristics of the patients

 
Serum leptin concentration

Serum leptin was measured in serum stored at -80 C. A commercially available leptin was used. The limit of sensitivity of the assay is 0.5 ng/mL, the intraassay variation under 9%, and the intraassay variation under 7%.

TNF-{alpha} was determined by ELISA as described previously (5).

Soluble TNF-receptors II were determined, as a biological marker of the TNF activity, with a commerically available kit (R & D Systems, Weisbaden, Germany) as published previously (5).

The means and SEM were calculated using the Winstat statistical program package (Kalmia Corp., Cambridge, MA). We performed the Friedman test to assess the significance between the data before administration of the first dose of TNF and the values obtained thereafter. A P-value of less than 0.01 was considered significant. The Pearson ranks correlation test was used to describe the correlation of leptin serum levels with TNF receptor serum levels.


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
We evaluated serum leptin levels in six patients with solid tumors before and after treatment with TNF-{alpha}, with (days 1, 3, and 5) or without interferon alpha-2 (5). Infusion of TNF (with or without interferon alpha-2) resulted in a significant increase in plasma leptin levels (P < 0.001) when baseline was compared with that found 12 h after TNF infusion (Fig. 1Go). Serum leptin levels rose from baseline 3.1 (SEM ± 0.28) ng/mL to 5.2 (SEM ± 0.6) after 12 h (P < 0.001). The increase was identical on days with or without simultaneous interferon therapy and was evident within 6 h after TNF infusion. TNF (with or without interferon alpha-2) administration was performed each day at the same time after breakfast. Furthermore, leptin was measured at similar time points in a healthy control group not receiving TNF. We did not observe a significant rise in leptin in these probands. In the control group of six healthy persons, there was only an insignificant 15% rise of 3 ng/mL up to 3.5 ng/mL (between 0800 in the morning and 0800 in the evening). Therefore the normal leptin variations during the day were excluded as a confounding factor.



View larger version (22K):
[in this window]
[in a new window]
  		Figure 1. Serum leptin levels increase after infusion of TNF. TNF was given over 120 min at 0, 24, 48, 72, and 96 h. Shown is the mean ± SEM (Friedman-test) of all patients and all cycles studied. The dash (-) marks the duration of the TNF infusion on the five seperate days. TNF therapy (iv) was combined with the sc interferon {alpha}-2 therapy on days 1, 3, and 5.

 
The leptin increase lasted a short time, and leptin serum levels returned to baseline within 24 h. Hence there was no difference between the start of a new cycle and repeated cycles after 21 days. A repeated cycle of TNF, given every 24 h for 5 days, resulted in a leptin increase each time in all patients studied.

As described previously (5), the serum levels of TNF receptors type II (TNF-R-II measured as markers of the TNF action) rose after TNF infusion. TNF receptor type II (at all timepoints and cycles measured) correlated with serum leptin (Table 2Go).


View this table:
[in this window]
[in a new window]
  		Table 2. TNF R-II levels before the TNF-infusions and after 12 h

 

   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
The data presented suggest that leptin serum levels are controlled by mediators of the host response in humans as well as in hamsters (4). Activation of the host response, associated with weight loss, is explained only in part by reduced appetite and, as shown here, by an increase in serum leptin, known to participate in control of body weight (2, 3). In view of the still confusing issue of the real function of leptin, we want to add the speculation that cytokine-induced leptin may participate in loss of appetite and wasting in chronic inflammatory disease. It remains unknown whether leptin plays a role in malignancy-associated anorexia and cachexia, as none of the patients studied was cachectic or complained about severe loss of appetite. This also explains why, in the six patients studied, pre-TNF leptin levels were not elevated relative to the body mass index. The TNF levels reached under TNF therapy were higher than in most patients with inflammatory disease. However, TNF concentrations sufficient to cause maximal stimulation of their cellular receptors may be reached locally, i.e. in the adipocytes themselves or in the microcirculation. It is conceivable that TNF synthesized by adipocytes acts in an autocrine or paracrine manner in regulating local leptin production. It is intriguing to speculate that elevated TNF production of adipose tissue in patients with adiposity not only adds to disturbance in insulin, signaling important in insulin resistance, but also adds to the elevated levels of leptin observed in these patients. In this model TNF alone would be sufficient to induce leptin synthesis, as suggested previously (4). Recently, however, it has been shown that, in immunocompromised not overweight (BMI (kg/m2) 22.2 ± 0.52) AIDS patients, serum leptin levels are not elevated despite high TNF levels (7). This discrepancy to our study might be explained by 1) the difference in the immune status of the tumor patients and AIDS patients; 2) difference in the ability of adipocytes to synthesize TNF in tumor patients and AIDS patients; or by 3) inhibitors of the TNF action in AIDS patients. The patients presented in our study all had a normal or even increased BMI ranging from 22–30, excluding cachexia as a confounding factor. Furthermore TNF was biologically active at each admission in each patient, as evidenced by the increase in TNF-receptors. The persistent increase in soluble TNF-receptors aand in leptin on each consecutive day argues strongly in favor of a sufficient biological action of TNF, despite the presence of soluble TNF-receptors (5).

Another potentially confounding issue is the daily variation in plasma leptin. It was shown (8) that there is a diurnal pattern of the 24 h leptin plasma level, with an approximate 50% rise from nadir (0900 in the morning) to peak (0100 in the early morning). In our study the highest plasma leptin levels were reached 12 h after TNF in the early evening. In addition, we did not observe a similar rise in serum leptin in healthy volunteers.

This pilot study showes that cytokines such as TNF {alpha} can control leptin levels in humans; however, further studies are needed to clarify the biological significance of the increase in leptin levels, as well as the mechanism of the cytokine-induced increase in serum leptin.


   Footnotes
 
1 P. P. Nawroth was supported by a grant from DFG and Schilling Stiftung Back

Received February 25, 1997.

Revised August 14, 1997.

Accepted August 22, 1997.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Beutler B, Cerami A. 1986 Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature. 7:79–128.
  2. Pelleymounter MA, Cullen MJ, Baker MB, et al. 1995 Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 69:540–543.
  3. Levin N, Nelson C, Gurney A, Vandlen R, Suavage F. 1996 Decreased food intake does not completely account for adiposity reduction after ob protein infusion. Proc Natl Acad Sci USA. 93:1726–1730.[Abstract/Free Full Text]
  4. Grunfeld C, Zhao C, Fuller J, et al. 1996 Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest. 97:2152–2157.[Medline]
  5. Boehme MWJ, Waldherr R, Kist A, et al. 1996 Kinetics of soluble TNF-receptors and soluble adhesion molecules ICAM-1, E-selectin, and VCAM-1 under systemic rh-TNF therapy. Eur J Clin Invest. 26:404–410.[CrossRef][Medline]
  6. Considine R, Sinha M, Heiman M, et al. 1996 Serum immunoreactive-leptin concentrations in normal weight and obese humans. N Engl J Med. 334:292–295.[Abstract/Free Full Text]
  7. Grunfeld C, Pang M, Shigenaga JK, et al. 1996 Serum leptin levels in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 81:4342–4346.[Abstract]
  8. Laughlin GA, Yen SSC. 1997 Hypoleptinemia in women athletes: absence of a diurnal rhythm with amenorrhea. J Clin Endocrinol Metab. 82:318–321.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. Lo, L. E. Bernstein, B. Canavan, M. Torriani, M. B. Jackson, R. S. Ahima, and S. K. Grinspoon
Effects of TNF-{alpha} neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome
Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E102 - E109.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. Schaffler, U. Muller-Ladner, J. Scholmerich, and C. Buchler
Role of Adipose Tissue as an Inflammatory Organ in Human Diseases
Endocr. Rev., August 1, 2006; 27(5): 449 - 467.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
P Harle, P Sarzi-Puttini, M Cutolo, and R H Straub
No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis.
Ann Rheum Dis, July 1, 2006; 65(7): 970 - 971.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. E. Trujillo, M.-J. Lee, S. Sullivan, J. Feng, S. H. Schneider, A. S. Greenberg, and S. K. Fried
Tumor Necrosis Factor {alpha} and Glucocorticoid Synergistically Increase Leptin Production in Human Adipose Tissue: Role for p38 Mitogen-Activated Protein Kinase
J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1484 - 1490.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M. A. Bedaiwy, T. Falcone, J. M. Goldberg, R. K. Sharma, D. R. Nelson, and A. Agarwal
Peritoneal fluid leptin is associated with chronic pelvic pain but not infertility in endometriosis patients
Hum. Reprod., March 1, 2006; 21(3): 788 - 791.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
M G Gnanalingham, A Mostyn, J Wang, R Webb, D H Keisler, N Raver, M C Alves-Guerra, C Pecqueur, B Miroux, T Stephenson, et al.
Tissue-specific effects of leptin administration on the abundance of mitochondrial proteins during neonatal development
J. Endocrinol., October 1, 2005; 187(1): 81 - 88.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Franchimont, S. Roland, T. Gustot, E. Quertinmont, Y. Toubouti, M.-C. Gervy, J. Deviere, and A. Van Gossum
Impact of Infliximab on Serum Leptin Levels in Patients with Crohn's Disease
J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3510 - 3516.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. L. Chan, J. Bullen, V. Stoyneva, A. M. DePaoli, C. Addy, and C. S. Mantzoros
Recombinant Methionyl Human Leptin Administration to Achieve High Physiologic or Pharmacologic Leptin Levels Does Not Alter Circulating Inflammatory Marker Levels in Humans with Leptin Sufficiency or Excess
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1618 - 1624.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. L. Chan, S. J. Moschos, J. Bullen, K. Heist, X. Li, Y.-B. Kim, B. B. Kahn, and C. S. Mantzoros
Recombinant Methionyl Human Leptin Administration Activates Signal Transducer and Activator of Transcription 3 Signaling in Peripheral Blood Mononuclear Cells in Vivo and Regulates Soluble Tumor Necrosis Factor-{alpha} Receptor Levels in Humans with Relative Leptin Deficiency
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1625 - 1631.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
P Harle, G Pongratz, C Weidler, R Buttner, J Scholmerich, and R H Straub
Possible role of leptin in hypoandrogenicity in patients with systemic lupus erythematosus and rheumatoid arthritis
Ann Rheum Dis, July 1, 2004; 63(7): 809 - 816.
[Abstract] [Full Text] [PDF]

Home page
 ReproductionHome page
L Veselsky, V Holan, J Dostal, and B Zelezna
Boar seminal immunosuppressive fraction attenuates the leptin concentration and restores the thymus mass during pregnancy in mice
Reproduction, May 1, 2004; 127(5): 581 - 585.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. P. Davis, R. Dreicer, D. Walsh, R. Lagman, and S. B. LeGrand
Appetite and Cancer-Associated Anorexia: A Review
J. Clin. Oncol., April 15, 2004; 22(8): 1510 - 1517.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Coll. Nutr.Home page
L. M. Gaetke, H. S. Oz, R. C. Frederich, and C. J. McClain
Anti-TNF-{alpha} Antibody Normalizes Serum Leptin in IL-2 Deficient Mice
J. Am. Coll. Nutr., October 1, 2003; 22(5): 415 - 420.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
D D Sin and S F P Man
Impaired lung function and serum leptin in men and women with normal body weight: a population based study
Thorax, August 1, 2003; 58(8): 695 - 698.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. M. Fernandez-Real and W. Ricart
Insulin Resistance and Chronic Cardiovascular Inflammatory Syndrome
Endocr. Rev., June 1, 2003; 24(3): 278 - 301.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
N. G. Mahutte, I. M. Matalliotakis, A. G. Goumenou, S. Vassiliadis, G. E. Koumantakis, and A. Arici
Inverse correlation between peritoneal fluid leptin concentrations and the extent of endometriosis
Hum. Reprod., June 1, 2003; 18(6): 1205 - 1209.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. E. Landman, J. J. Puder, E. Xiao, P. U. Freda, M. Ferin, and S. L. Wardlaw
Endotoxin Stimulates Leptin in the Human and Nonhuman Primate
J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1285 - 1291.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
R. R. Gonzalez, K. Leary, J. C. Petrozza, and P. C. Leavis
Leptin regulation of the interleukin-1 system in human endometrial cells
Mol. Hum. Reprod., March 1, 2003; 9(3): 151 - 158.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
S E Moore, G Morgan, A C Collinson, J A Swain, M A O'Connell, and A M Prentice
Leptin, malnutrition, and immune response in rural Gambian children
Arch. Dis. Child., September 1, 2002; 87(3): 192 - 197.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
M. Lopez-Alarcon, C. Garza, J.-P. Habicht, L. Martinez, V. Pegueros, and S. Villalpando
Breastfeeding Attenuates Reductions in Energy Intake Induced by a Mild Immunologic Stimulus Represented by DPTH Immunization: Possible Roles of Interleukin-1{beta}, Tumor Necrosis Factor-{alpha} and Leptin
J. Nutr., June 1, 2002; 132(6): 1293 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
B. N. Finck and R. W. Johnson
Anti-inflammatory agents inhibit the induction of leptin by tumor necrosis factor-alpha
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2002; 282(5): R1429 - R1435.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Vigano, E. Somigliana, R. Matrone, A. Dubini, C. Barron, M. Vignali, and A. M. di Blasio
Serum Leptin Concentrations in Endometriosis
J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1085 - 1087.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
R. FAGGIONI, K. R. FEINGOLD, and C. GRUNFELD
Leptin regulation of the immune response and the immunodeficiency of malnutrition
FASEB J, December 1, 2001; 15(14): 2565 - 2571.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
G. De Placido, C. Alviggi, C. Carravetta, M.L. Pisaturo, V. Sanna, M. Wilding, G.M. Lord, and G. Matarese
The peritoneal fluid concentration of leptin is increased in women with peritoneal but not ovarian endometriosis
Hum. Reprod., June 1, 2001; 16(6): 1251 - 1254.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
G. Fruhbeck, J. Gomez-Ambrosi, F. J. Muruzabal, and M. A. Burrell
The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation
Am J Physiol Endocrinol Metab, June 1, 2001; 280(6): E827 - E847.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
G. Fantuzzi and R. Faggioni
Leptin in the regulation of immunity, inflammation, and hematopoiesis
J. Leukoc. Biol., October 1, 2000; 68(4): 437 - 446.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. C. CREUTZBERG, E. F. M. WOUTERS, I. M. L. VANDERHOVEN-AUGUSTIN, M. A. DENTENER, and A. M. W. J. SCHOLS
Disturbances in Leptin Metabolism Are Related to Energy Imbalance during Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1239 - 1245.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Matarese, C. Alviggi, V. Sanna, J. K. Howard, G. M. Lord, C. Carravetta, S. Fontana, R. I. Lechler, S. R. Bloom, and G. De Placido
Increased Leptin Levels in Serum and Peritoneal Fluid of Patients with Pelvic Endometriosis
J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2483 - 2487.
[Abstract] [Full Text]

Home page
 Nephrol Dial TransplantHome page
A. Widjaja, J. T. Kielstein, R. Horn, A. von zur Muhlen, V. Kliem, and G. Brabant
Free serum leptin but not bound leptin concentrations are elevated in patients with end-stage renal disease
Nephrol. Dial. Transplant., June 1, 2000; 15(6): 846 - 850.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. M. Rice, J. N. Fain, and S. A. Rivkees
A1 Adenosine Receptor Activation Increases Adipocyte Leptin Secretion
Endocrinology, April 1, 2000; 141(4): 1442 - 1445.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. N. Vgontzas, D. A. Papanicolaou, E. O. Bixler, K. Hopper, A. Lotsikas, H.-M. Lin, A. Kales, and G. P. Chrousos
Sleep Apnea and Daytime Sleepiness and Fatigue: Relation to Visceral Obesity, Insulin Resistance, and Hypercytokinemia
J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1151 - 1158.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. L. Fawcett, A. S. Waechter, L. B. Williams, P. Zhang, R. Louie, R. Jones, M. Inman, J. Huse, and R. V. Considine
Tumor Necrosis Factor-{alpha} Inhibits Leptin Production in Subcutaneous and Omental Adipocytes from Morbidly Obese Humans
J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 530 - 535.
[Abstract] [Full Text]

Home page
 Mol Hum ReprodHome page
D. Chardonnens, P. Cameo, M.L. Aubert, F.P. Pralong, D. Islami, A. Campana, R.C. Gaillard, and P. Bischof
Modulation of human cytotrophoblastic leptin secretion by interleukin-1{alpha} and 17{beta}-oestradiol and its effect on HCG secretion
Mol. Hum. Reprod., November 1, 1999; 5(11): 1077 - 1082.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
D R Murdoch, E Rooney, H J Dargie, D Shapiro, J J Morton, and J J V McMurray
Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure
Heart, September 1, 1999; 82(3): 352 - 356.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
A BALLINGER
Divergency of leptin response in intestinal inflammation
Gut, May 1, 1999; 44(5): 588 - 589.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
C. S. Mantzoros
The Role of Leptin in Human Obesity and Disease: A Review of Current Evidence
Ann Intern Med, April 20, 1999; 130(8): 671 - 680.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
N. TAKABATAKE, H. NAKAMURA, S. ABE, T. HINO, H. SAITO, H. YUKI, S. KATO, and H. TOMOIKE
Circulating Leptin in Patients with Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., April 1, 1999; 159(4): 1215 - 1219.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
M Barbier, C Cherbut, A C Aube, H M Blottiere, and J P Galmiche
Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats
Gut, December 1, 1998; 43(6): 783 - 790.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Van den Berghe, P. Wouters, L. Carlsson, R. C. Baxter, R. Bouillon, and C. Y. Bowers
Leptin Levels in Protracted Critical Illness: Effects of Growth Hormone-Secretagogues and Thyrotropin-Releasing Hormone
J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3062 - 3070.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
B. N. Finck, K. W. Kelley, R. Dantzer, and R. W. Johnson
In Vivo and in Vitro Evidence for the Involvement of Tumor Necrosis Factor-{alpha} in the Induction of Leptin by Lipopolysaccharide
Endocrinology, May 1, 1998; 139(5): 2278 - 2283.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zumbach, M. S.
Right arrow Articles by Nawroth, P. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zumbach, M. S.
Right arrow Articles by Nawroth, P. P.

HOME HELP